drugset
drugset / Trial / NCT00761306

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

NCT00761306 ↗

Phase 2 Completed 74 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 / 11492A.

Timeline

Start
2007-06
Primary completion
2008-09
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 5 mg Oral
Subject Vortioxetine Unknown 10 mg Oral

Indications

major depressive disorder